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ABSTRACT 
Background: Substance use is common among people with bipolar I disorder, a mental illness 
marked by periods of mania and depression.  Although substance use affects people with bipolar 
I disorder more than the general population, and psychotherapy-inclusive treatments show 
promise in treating comorbid substance use and bipolar I disorders, no studies to our knowledge 
have applied these treatments to bipolar I disorder people with sub-threshold substance use.  The 
public health importance of minimizing substance use in people with bipolar I disorder is to 
minimize impacts such as hospitalization costs, lost compensation, and early mortality, through 
control of symptoms. 
We conducted secondary analyses to determine whether one such treatment, integrated 
risk reduction intervention (IRRI), decreased substance use spectrum measures more than 
standard care, psychiatric care with medical monitoring (PCMM).  The primary study was a 
randomized controlled trial conducted to reduce medical risks and minimize morbidity and 
mortality in bipolar I disorder participants.  In our current secondary analyses, we hypothesized 
that 1) all participants would have decreased substance use spectrum measures after 6 months of 
either treatment, 2) IRRI participants would have a greater decrease than PCMM participants, 
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and 3) the change in substance use spectrum measures would decrease more among those with a 
prior alcohol use disorder than those with no prior alcohol use disorder. 
Methods: Participants were recruited in Pittsburgh, PA and randomly assigned to IRRI 
(n=58) or PCMM (n=56).  Four substance use spectrum measures from the Self-Report Last 
Month Substance Use Spectrum assessment (SUBS-SR – Last Month) were evaluated, if 
completed at both study entry and 6 months.  Wilcoxon signed rank tests, Wilcoxon rank sum 
tests, and multiple linear regression were used for analyses. 
Results: There were no significant changes in substance use spectrum measures from 
study entry to 6 months among all participants.  There were no clinically meaningful differences 
in substance use measures between IRRI and PCMM participants or between participants with 
versus without a lifetime alcohol use disorder. 
Conclusions: The current format of IRRI does not appear to have an effect on substance 
use spectrum measures after 6 months of treatment. The public health implications of this study 
are that further study is needed to identify the effectiveness of psychotherapy-related treatment 
of sub-threshold substance use in bipolar I disorder patients. 
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1.0  INTRODUCTION 
1.1 BIPOLAR I DISORDER 
Worldwide, 60 million people are affected with the mental illness bipolar disorder ("WHO | 
Mental disorders | Fact sheet N°396," October 2014).  About 2.6% of the United States’ (U.S.) 
adult population (5.4 million adults) has bipolar disorder ("Gender: 2000 | Census 2000 brief," 
September 2001; Kessler, Chiu, Demler, Merikangas, & Walters, 2005), which is characterized 
by episodes of mania and depression.  One type, bipolar I disorder, makes up about 42% of all 
bipolar cases (Kroon et al., 2013).  Thus, bipolar I disorder is present in about 2.3 million U.S. 
adults.  In 1991, U.S. costs for bipolar disorder amounted to $45 billion, of which $17 billion 
accounted for lost compensation (Wyatt & Henter, 1995).  By 2009, bipolar-related costs were 
estimated at $151 billion in the U.S. (Dilsaver, 2011). 
Bipolar I disorder is defined by having at least one lifetime episode of mania, marked by 
an abnormal and persistent elevated mood and, usually, episodes of major depression (American 
Psychiatric Association. & American Psychiatric Association. Task Force on DSM-IV., 2000).  
Although bipolar I disorder typically onsets around 18 years of age, with a first manic episode in 
the early 20’s (Kennedy et al., 2005), it can onset anytime from childhood to 60+ years of age 
(American Psychiatric & American Psychiatric Association, 2013).  Kroon et al. (2013) found 
that the month and season of onset of bipolar I disorder are, interestingly, unrelated to the month 
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and season of birth.  Bipolar disorder is also unrelated to race, ethnicity, and family income and 
is inversely related to education level (Merikangas et al., 2007).  The relationship between 
bipolar I disorder and marital status shows higher rates in those who are separated, divorced, or 
widowed than in those who are married or have never been married (American Psychiatric & 
American Psychiatric Association, 2013).  When viewing bipolar I disorder incidence rates by 
urban classification, no difference was found between urban and non-urban areas (Kroon et al., 
2013).  However, there is a high incidence of bipolar I disorder in deprived areas (~0.9 per 
10,000 person years) compared with non-deprived areas (~0.4 per 10,000 person years) (Kroon 
et al., 2013).  (Deprivation assessment was based on a combination of factors such as number of 
people per area, average income, and number of people receiving social security.)  This chronic 
illness often impacts work, social life, and finances and can lead to disability or suicide. 
Patients with bipolar disorder die about 9 years earlier than people in the general 
population (Crump, Sundquist, Winkleby, & Sundquist, 2013).  The majority of excess deaths in 
bipolar disorder are secondary to medical conditions such as obesity and substance use 
(Roshanaei-Moghaddam & Katon, 2009).  Medical illnesses such as cardiovascular disease and 
diabetes mellitus create increased mortality for patients with bipolar disorder compared with the 
general population (Crump et al., 2013).  Medications used to treat bipolar disorder, such as 
mood stabilizers and antipsychotics, cause obesity and type 2 diabetes, among other illnesses 
(Roshanaei-Moghaddam & Katon, 2009).  Most patients with bipolar disorder are overweight or 
obese (Fagiolini et al., 2002; Wang et al., 2006).  It is important to stabilize the symptoms of 
bipolar disorder to avoid the disturbing impacts on life, work, and monetary resources. 
To stabilize the symptoms of bipolar disorder would mean to prevent manic and 
depressive episodes and to alleviate the manifestations (i.e. sleeplessness, grandiosity, fatigue, 
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indecisiveness, etc.) of episodes that do occur.  Bipolar disorder symptom stabilization is often 
impeded by physical and psychiatric comorbidities such as diabetes mellitus, migraines, 
cardiovascular disease, anxiety, attention deficit hyperactivity disorder, and substance use 
disorder (Merikangas et al., 2007; Sagman & Tohen, 2012).  The majority of patients with 
bipolar I disorder (86.2%) have at least three psychiatric comorbidities (Merikangas et al., 2007).  
One that is highly prevalent and potentially problematic in stabilization of bipolar disorder 
symptoms is substance use disorder, as shown in the next section. 
1.2 SUBSTANCE USE 
1.2.1 SUBSTANCE USE IN BIPOLAR I DISORDER 
The National Institute of Mental Health (NIMH) Epidemiologic Catchment Area study showed 
that 60.7% of people with bipolar I disorder have a substance abuse diagnosis, 46.2% have an 
alcohol abuse/dependence diagnosis, and 40.7% have a drug abuse/dependence diagnosis (Regier 
et al., 1990).  Substance use disorders include dependence and abuse of alcohol, amphetamines, 
caffeine, cannabis, cocaine, hallucinogens, inhalants, nicotine, opioids, phencyclidine (PCP), and 
sedatives/hypnotics/anxiolytics (American Psychiatric Association. & American Psychiatric 
Association. Task Force on DSM-IV., 2000). 
People with comorbid bipolar and substance use disorders have greater health risks than 
bipolar people without substance use disorders.  For example, people with comorbid bipolar and 
substance use disorders have worse social functioning (Mazza et al., 2009), conceptual reasoning 
skills, and visual memory (Marshall et al., 2012) and are more likely to be suicide attempters 
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(Carrà, Bartoli, Crocamo, Brady, & Clerici, 2014; Dalton, Cate-Carter, Mundo, Parikh, & 
Kennedy, 2003) than bipolar patients without a substance use disorder.  Bipolar disorder patients 
who use tobacco are also at a greater risk of coronary heart disease than bipolar patients who do 
not use tobacco (Garcia-Portilla et al., 2010).  Interestingly, a study conducted among veterans 
with bipolar disorder showed that those who use substances, versus those who do not, are about 
three times more likely to have psychiatric hospitalizations (Hoblyn, Balt, Woodard, & Brooks, 
2009).  As such, even without crossing the threshold of being a disorder, substance use has 
particularly adverse consequences in people with bipolar disorder. 
Sub-threshold substance use disorder is when a person has symptoms of the disorder, but 
not enough symptoms to meet criteria for a diagnosis (Sbrana et al., 2005).  In 2005, Sbrana et al. 
discussed the idea that substance use disorders are best approached as a spectrum, to include 
threshold and sub-threshold use.  Although this thought was not in line with the DSM-IV (in use 
at that time), it is consistent with the current DSM-5 approach, published in 2013.  The DSM-IV 
separates substance use disorders into two categories, substance abuse and substance 
dependence.  The DSM-5 combines these into one category, substance use disorders, and 
includes the categories of mild, moderate, and severe.  This spectrum approach allows for 
diagnosis of sub-threshold substance use.  Due to the negative effects on patients with substance 
use disorder at any point in the disorder’s spectrum, it is imperative that substance use be 
minimized among people with bipolar I disorder, even if it has not reached the level of a 
substance use disorder. 
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1.2.2 SUBSTANCE USE TREATMENT IN BIPOLAR I DISORDER 
Studies on treatment for comorbid bipolar and substance use disorders have historically focused 
on pharmacotherapy (Brown, Nejtek, Perantie, & Bobadilla, 2002; Brown, Nejtek, Perantie, 
Orsulak, & Bobadilla, 2003; Chengappa, Gershon, & Levine, 2001) and have shown mixed 
results of the pharmacologic effects on these comorbid disorders.  Some of the pharmacotherapy 
treatments used include mood stabilizers, antidepressants, and atypical antipsychotics (Matson et 
al., 2006).  The mixed effects include weight gain, sedation, and tremors (Mago, Borra, & 
Mahajan, 2014).  Psychotherapy has been a successful treatment for bipolar disorder, but few 
studies have used it to treat comorbid bipolar and substance use disorders. 
Weiss et al. (2000) conducted a pilot study, which incorporated psychotherapy as a 
treatment for comorbid bipolar and substance use disorders.  The study used hour-long integrated 
group therapy sessions among 45 participants for up to 20 weeks.  This therapy was designed to 
incorporate recovery and relapse processes that are found in both bipolar disorder treatments and 
substance use disorder treatments and included psychoeducation and group psychotherapy.  The 
integrated group therapy sessions consisted of a “check-in” on patients’ progress over the prior 
week, a review of the major points from the prior week’s session, a didactic session and 
discussion of the current session topic, and 2-page session summary handouts (Weiss, Najavits, 
& Greenfield, 1999).  The sessions had an “open” format, rather than building upon the prior 
topics, so that people can start the therapy at any point.  The control group received 6 monthly 
therapy sessions (Weiss et al., 2000).  Participants in the integrated group therapy had 
significantly lower drug and alcohol scores on the Addiction Severity Index (ASI) fifth edition 
(McLellan et al., 1992) and had improved mood compared with those in the control group.  
Weiss et al. (2000) also found that participants in the 20-week versus 12-week integrated group 
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therapy did better with decreasing drug and alcohol use.  In 2007, Weiss, et al. published on a 
randomized controlled trial among 62 participants comparing 20 weeks of integrated group 
therapy with 20 weeks of group drug counseling.  Integrated group therapy still focused on both 
mood and substance use related issues, while group drug counseling focused only on substance 
use related issues.  They found that participants in the integrated group therapy had decreased 
drug and alcohol use compared with the control group.  After separating substance use into drugs 
and alcohol, they found that the decrease applied to alcohol use, but not to drug use.  There were 
no differences in mood found between the groups.  Weiss et al. (2009) have since created a 
“community-friendly” version of the integrated group therapy.  In this version, adjusted to be 
more adaptable in community treatment programs, the integrated group therapy was altered to be 
shorter (12 weeks) and administrable by substance use disorder counselors who had no formal 
training in counseling on mood disorders.  Results showed that the 31 integrated group therapy 
participants did better in decreasing drug and alcohol use than the 30 participants in the control 
group (group drug counseling).  During treatment, the integrated group therapy participants also 
had more improved mood than the control group. 
To our knowledge, the only other psychotherapy-inclusive treatment focused on 
comorbid bipolar and substance use disorders was conducted by Jones et al. (2011).  They 
reported on a preliminary, uncontrolled intervention in five participants with comorbid bipolar 
and substance use disorders.  The intervention used motivational interviewing to identify a 
patient’s concerns and life goals, followed by identification of how bipolar disorder and 
substance use affected these.  Cognitive behavioral therapy strategies were then used to guide 
patients into making related changes that could help them address their concerns and goals.  
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They found that the intervention helped reduce substance use in four of the five participants, but 
did not find clear indications of mood improvement. 
These studies have shown that incorporating a psychotherapy component into treatment 
for people with comorbid bipolar and substance use disorders can have a positive impact on 
substance use and, possibly, mood symptoms.  The optimal situation would be to give patients 
tools to regulate their substance use so they can avoid substance abuse and dependence.  The 
current secondary analyses aim to determine whether substance use was reduced in participants 
with bipolar I disorder, who were not abusing or dependent on substances at study entry, after 
participation in an integrated risk reduction intervention (IRRI). 
The study on which the current secondary analyses were run was expected to reduce 
several modifiable medical risks.  It is important to educate people with bipolar disorder about 
how to lead a healthy lifestyle and the potential consequences of not doing so.  If patients are 
able to manage their substance use, they will be less likely to abuse or become dependent on 
substances.  The secondary analyses of the current study, which was built on a strong healthy 
lifestyle psychoeducation program, are expected to show a positive impact of IRRI on 
participants’ substance use and related factors. 
The current study has a larger sample size than those conducted by Jones et al. (2011) 
and Weiss et al. (2000, 2007, 2009).  These prior studies focused on patients with comorbid 
bipolar disorder and substance use disorder, whereas the current analyses focus on bipolar 
disorder patients who use substances and are not currently abusing or dependent on substances.  
Due to the many harmful effects of substances on bipolar disorder patients, as noted above in 
section 1.2 (e.g., problems with conceptual reasoning and increased risk of coronary heart 
disease, suicide attempts, and psychiatric hospitalizations), it is imperative that treatments help 
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patients manage their substance use.  In addition, if a patient has previously abused or been 
dependent on substances and has remitted, it is critical to treat this patient to avoid relapse.  The 
current study will add a sizeable sample to the literature addressing substance use in patients 
with bipolar I disorder who are not currently abusing or dependent on substances.  The study 
treatment, IRRI, addresses substance use through education, guidance in maneuvering an 
individual’s personal barriers, and reinforcement of progress and goals (Frank et al., 2014). 
A randomized clinical intervention trial in treatment-seeking, adult participants with 
bipolar I disorder was conducted to determine the effectiveness of IRRI in reducing modifiable 
risks.  The current secondary analyses focus on determining whether IRRI reduced substance use 
and related factors.  We hypothesize that the successful psychiatric treatment (IRRI or 
psychiatric care with medical monitoring (PCMM)) of bipolar I disorder participants will reduce 
substance use and related factors after 6 months of treatment because there will be regular 
attention and monitoring of the patient’s medical status.  In addition, participants treated with 
IRRI compared with PCMM will have a greater reduction of substance use and related factors 
because IRRI includes a healthy lifestyle behaviors program, intended to help participants 
achieve a balanced lifestyle through education.  The gap in current knowledge, which these 
analyses intend to address, is psychotherapy-inclusive treatment for patients with bipolar I 
disorder who use substances but are not currently abusing or dependent on substances. 
1.3 SUMMARY 
The population of interest is a subset of people with bipolar disorder.  They have bipolar I 
disorder – in remission, are overweight with a body mass index of >25, and do not currently have 
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a substance use disorder, although they made have had one in the past and could currently be 
using substances. 
1.3.1 SPECIFIC AIMS AND HYPOTHESES 
The specific aims and hypotheses of this study are: 
1. Aim: To determine whether substance use, use of substances or drugs as self-medication, 
symptoms of substance use disorder, and total substance use spectrum scores from the Self-
Report Last Month Substance Use Spectrum assessment (SUBS-SR – Last Month) decrease 
in participants with bipolar I disorder who are overweight or obese, after undergoing 6 
months of psychiatric treatment (IRRI or PCMM). 
1.1. Hypothesis: In participants with bipolar I disorder who are overweight or obese, 
substance use, use of substances or drugs as self-medication, symptoms of substance use 
disorder, and total substance use spectrum SUBS-SR – Last Month scores will decrease 
after 6 months of psychiatric treatment (IRRI or PCMM). 
2. Aim: To determine whether there is a greater decrease of substance use, use of substances or 
drugs as self-medication, symptoms of substance use disorder, and total substance use 
spectrum SUBS-SR – Last Month scores in participants with bipolar I disorder who are 
overweight or obese, after undergoing 6 months of IRRI treatment compared with PCMM 
treatment. 
2.1. Hypothesis: In participants with bipolar I disorder who are overweight or obese, there 
will be a greater decrease of substance use, use of substances or drugs as self-
medication, symptoms of substance use disorder, and total substance use spectrum 
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SUBS-SR – Last Month scores after undergoing 6 months of IRRI treatment compared 
with PCMM treatment. 
3. Aim: Among participants with bipolar I disorder who are overweight or obese, to determine 
whether there is a difference between participants with a prior alcohol use disorder compared 
with participants who do not have a prior alcohol use disorder in the change of substance use, 
use of substances or drugs as self-medication, symptoms of substance use disorder, and total 
substance use spectrum SUBS-SR – Last Month scores after undergoing 6 months of 
psychiatric treatment (IRRI or PCMM) and to determine whether having a prior alcohol use 
disorder modifies the relative effect of IRRI treatment versus PCMM treatment. 
3.1. Hypothesis: Among participants with bipolar I disorder who are overweight or obese, 
participants with a prior alcohol use disorder will have a larger change of substance use, 
use of substances or drugs as self-medication, symptoms of substance use disorder, and 
total substance use spectrum SUBS-SR – Last Month scores compared with participants 
who do not have a prior alcohol use disorder after undergoing 6 months of psychiatric 
treatment (IRRI or PCMM).  In addition, having a prior alcohol use disorder will 
amplify the relative effect of IRRI treatment versus PCMM treatment. 
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2.0  METHODS 
This thesis involves a secondary analysis of data collected from a randomized clinical trial.  
Sections 2.1-2.3 below focus on the main trial and sections 2.4-2.5 address elements of the 
current secondary analyses of these data. 
2.1 STUDY DESIGN 
Treatment-seeking participants were recruited from Western Psychiatric Institute and Clinic 
outpatient and research facilities, University of Pittsburgh Medical Center general public and 
employees, and University of Pittsburgh students and staff.  Participants received a verbal 
explanation of the prospective randomized intervention before giving written informed consent.  
The study was approved by the University of Pittsburgh Institutional Review Board 
(NCT00746343). 
The aims of the main trial were to determine whether IRRI was a superior treatment to 
PCMM in reducing medical risks and minimizing morbidity and mortality associated with 
bipolar I disorder, the results of which were published by Frank et al. in 2014.  In order to 
address these aims, patients with bipolar I disorder and a body mass index (BMI) of ≥ 25 kg/m2, 
who were otherwise healthy, were selected to participate.  Noteworthy to the current secondary 
analyses of data from that main trial, participants could not have a current substance use 
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disorder, but may have had a remitted substance use disorder at study screening.  Bipolar I 
disorder and substance use disorder (past, current, or never) were identified via the Structured 
Clinical Interview for DSM-IV Axis I Disorders (SCID-I), a semi-structured, clinician 
administered, diagnostic interview based on criteria from the Diagnostic and Statistical Manual 
of Mental Disorders fourth edition (DSM-IV) (First, Spitzer, Gibbon, & Williams, 1995). 
Participants had to be 18 to 55 years of age, with their bipolar I disorder remitted for at 
least four consecutive weeks prior to study entry.  Remission was defined as a score of ≤7 on 
both the Hamilton Rating Scale for Depression (17-item; HRSD-17) (Hamilton, 1960) and the 
Young Mania Rating Scale (YMRS) (Young, Biggs, Ziegler, & Meyer, 1978) and a score of <3 
on the Clinical Global Impressions for Bipolar Disorder Scale (CGI-BP-S) (Spearing, Post, 
Leverich, Brandt, & Nolen, 1997).  Participants were assessed for remission by these clinician-
administered scales at least twice during the four weeks prior to study entry.  Those with ultra-
rapid cycling bipolar I disorder (>4 episodes in 6 months), pervasive developmental disorder, 
antisocial personality disorder, schizophrenia, or organic mental disorder as identified by the 
SCID-I were ineligible to participate.  Unstable, severe medical illness requiring immediate, 
intense treatment as identified by the patient or the patient’s medical record, unwillingness or 
inability to comply with study requirements, and inability to provide informed consent were all 
study exclusions.  The last participation criterion for the main trial was that women planning to 
become or currently pregnant or breast-feeding were excluded.  This was based on self-report, 
except when there was reason to suspect pregnancy in women not using reliable birth control, in 
which case a pregnancy test was performed. 
To ensure balance between treatment groups, a stratified permuted block design was 
utilized.  The strata were low risk and high risk and the blocks were a size of four.  The strata 
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risk level was based on an algorithm that indicated the stability and complexity of the 
participant’s medication regimen.  After random allocation to either IRRI or PCMM, participants 
remained in their assigned group for the entire 24-month study period. 
The study duration was divided into two phases: phase 1 constituted the first 6 months 
and phase 2 the remaining 18 months.  During phase 1, treatment took place up to weekly and 
consisted of 15-17 structured psychoeducation modules for IRRI participants (Table 1).  In phase 
2, participants attended 5-7 monthly sessions during study months 7 through 12 and 4-5 quarterly 
sessions during study months 13 through 24.  The timing and number of the phase 2 sessions 
depended on when the phase 1 sessions ended.  The purpose of the phase 2 sessions was to 
follow-up and to assess the progress of the IRRI participants’ healthy lifestyle changes.  Included 
in the phase 2 IRRI sessions were: i) assessments of sleep/wake and social rhythm patterns, 
weight, nutrition, and physical activity; ii) assessments of progress toward participants’ 
individual goals; iii) adherence emphasis; and iv) assistance with progress barriers including 
addressing relapses. 
2.2 INTERVENTIONS 
IRRI consisted of three components and PCMM consisted of two, also described in Frank et al.,  
2014.  Both interventions included psychopharmacologic treatment and medical monitoring, 
although in PCMM, medical monitoring was less intensive than in IRRI.  The third component in 
IRRI was the healthy lifestyle behaviors program. 
 
 
14 
Psychopharmacologic treatment (IRRI and PCMM) 
An attempt was made to limit participants to one or two of the following medications: 
lithium, divalproex, aripiprazole, and quetiapine.  This was done to minimize the variance 
associated with an extensive regimen of different psychiatric medications.  However, some 
participants remained on already stable medication regimens.  The study psychiatrist made 
efforts to balance the participants’ mood symptoms with medication side effects, such as weight 
gain.  The Bipolar Disorder Visit Form (BDVF) was used to guide the psychiatrist in monitoring 
the participants’ medications as related to all states of bipolar disorder (remitted, manic, 
hypomanic, and depressed).  The BDVF was adapted from the Clinical Monitoring Form (CMF) 
used in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) 
(Sachs, Guille, & McMurrich, 2002; Sachs et al., 2003). 
Medical monitoring (IRRI and PCMM) 
Participants saw the nurse monthly except when symptomatic; then they visited twice a 
month.  Similarly, they saw the psychiatrist every two months except when symptomatic at 
which time they went monthly.  Visits with the nurse or psychiatrist lasted about 30 minutes.  
The nurse assessed and monitored the participants’ psychiatric symptoms, psychiatric 
medications, and medication side effects, and conducted safety evaluations.  Between visits, the 
nurses took phone calls from participants and notified psychiatrists of any psychiatric related 
issues.  Labs were taken at study entry, every six months, and as needed for medical issues.  For 
abnormal lab values, participants were referred to their PCP or medical specialist.  The medical 
team (psychiatrist, nurse, and, when applicable, lifestyle coach) met weekly to discuss the 
participants’ status including labs and recommendations. 
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IRRI participants only: The nurse worked to make sure IRRI participants adhered to 
medical and psychiatric treatments, including pharmacotherapy and the healthy lifestyle 
behaviors program and notified the psychiatrist and lifestyle coach of the participants’ 
adherence.  Additionally, the nurse coordinated and assisted with communications among the 
participant, psychiatrist, lifestyle coach, primary care physician (PCP) or medical specialist, and 
study endocrinologist or cardiologist (when needed). 
Healthy lifestyle behaviors program (IRRI only) 
During one hour sessions, the lifestyle coach administered the healthy lifestyle behaviors 
program using the Social Rhythm Metric-5 (SRM-5) (Monk, Flaherty, Frank, Hoskinson, & 
Kupfer, 1990).  The program was based on the thought that stabilizing social rhythms and 
sleep/wake cycles helps minimize medical risk factors.  It consisted of structured modules 
designed to educate participants about healthy lifestyle behaviors and risk reduction, promote 
quality of life, and help participants establish a healthy routine, adhere to treatments and 
medications, increase physical activity, lose or maintain weight, and if applicable, cease 
smoking.  Substance use is an important modifiable medical risk, which was discussed in all 
pertinent modules. 
In the healthy lifestyle behaviors program, the participants identified goals most 
important to them and the coach tried to incorporate some aspect of these goals in the modules 
early on, without changing the order of the modules.  This helped build a bond with the 
participants and give them early gratification for making progress toward their goals.  
Participants set goals weekly and discussed the prior week’s behavioral change goals with the 
coach.  Together, they adjusted the behavior modification as needed (advanced or adjusted the 
modification).  The coach also provided encouragement to help participants accomplish goals 
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and adhere to medication and treatment.  Other tools used in the study were daily diet records, 
calorie counter books, and pedometers. 
2.3 STUDY STAFF 
Staff experienced in treating bipolar disorder included psychiatrists, psychologists, social 
workers, and Bachelor’s or Master’s level psychiatric nurses.  Lifestyle coaching was conducted 
by a health education specialist educated in nutrition and exercise physiology or, when she was 
unavailable, by a psychiatric social worker trained in behavioral modification techniques such as 
interpersonal and social rhythm therapy.  The lifestyle coaches were trained over two days in 
motivational interviewing techniques, sleep medicine, behavioral weight control, and nutrition 
by experts in each of these fields.  Dr. Ellen Frank supervised the health education specialist 
biweekly to ensure program adherence. 
Nurses worked with either IRRI participants or PCMM participants and were blind to the 
other intervention’s participants’ progress.  An additional nurse who was blind to all participants’ 
treatment assignments conducted weekly chart reviews to ensure that the treatment algorithms 
were being administered correctly and that they were consistent across both treatment groups. 
2.4 MEASURES 
The outcomes of interest for the current secondary analyses were the changes in SUBS-SR – 
Last Month substance use spectrum measure scores from study entry to 6 months.  The SUBS-
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SR – Last Month was adapted from the Structured Clinical Interview for Substance Use 
Spectrum (SCI-SUBS), a validated tool that identifies one’s substance-related experiences, 
symptoms, and behaviors (Sbrana et al., 2003).  The SUBS assessments consist of 131 questions 
each covering six domains: I) substance use (medications and recreational drugs), II) substance 
sensitivity (mood changes, anxiety attacks, and strong sensations), III) use of substances or drugs 
as self-medication (mood/anxiety, improving performance, social distribution, weight control, 
body image, and other conditions), IV) sensation seeking (strong emotions), V) attention 
deficit/hyperactivity symptoms, and VI) symptoms of substance use disorder (abuse, addiction, 
tolerance, withdrawal, and intoxication) (Bizzarri et al., 2007).  The SUBS-SR – Last Month was 
completed at study entry and 6, 12, 18, and 24 months of treatment.  The total score of the 
assessment was used as an indication of where a person lies on the spectrum of substance use.  
As a measure of severity of the prior month’s substance use, the scores of domain I (substance 
use; 22 questions), domain III (use of substances or drugs as self-medication; 55 questions), and 
domain VI (symptoms of substance use disorder; 23 questions) were used.  All four of these 
scores were determined at both study entry and month 6, when the SUBS-SR – Last Month was 
completed.  The outcomes were the difference in score from study entry to the follow-up 
assessment at 6 months of the substance use, use of substances or drugs as self-medication, 
symptoms of substance use disorder, and total SUBS-SR – Last Month measures. 
2.5 STATISTICAL ANALYSES 
The baseline characteristics of the total sample, of each treatment group individually, and by 
prior alcohol use disorder group are described.  These characteristics are age at onset of first 
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manic episode, age at study screening, gender, race, ethnicity, marital status, education, 
employment status, depression level from the HRSD-25, mania level from the YMRS, SUBS-SR 
– Last Month question 3 “In the past month, have you had periods in which you drank a lot of 
alcohol?,” and prior substance use disorders from the SCID-I.  Had there been any significant 
baseline differences between the IRRI and PCMM groups, they would have been adjusted for in 
subsequent analyses. 
To test the first hypothesis, the paired (study entry and 6 months) continuous outcomes 
(substance use score, self-medication score, substance use disorder symptoms score, and overall 
substance use spectrum score from the SUBS-SR – Last Month) for all participants were 
compared.  Due to the ‘absence of current substance use disorders’ enrollment criteria, the 
outcomes were non-normally distributed and positively skewed (i.e., to the right) among 
participants.  Thus, the data were log-transformed.  This did not normalize the data, so a one-
sided Wilcoxon signed rank test was used to analyze the non-transformed data.  There was 80% 
power to detect a medium effect size of 0.272 between the paired (study entry and 6 months) 
substance use, self-medication, substance use disorder symptoms, and overall substance use 
spectrum scores from the SUBS-SR – Last Month, with α=0.05 based on a one-sided paired t-test 
using all participants who completed at least one outcome at both time points (Table 2). 
The continuous outcomes for the second and third hypotheses were the differences from 
study entry to 6 months of the SUBS-SR – Last Month total and domain I, III, and VI scores.  To 
test the second hypothesis, the change-score outcomes of the IRRI group were compared with 
those of the PCMM group (i.e., two independent samples).  As the data were non-normally 
distributed, they were log-transformed.  This did not normalize the data, so a one-sided 
Wilcoxon rank sum test was used to analyze the non-transformed data.  There was 80% power to 
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detect a large effect size of 0.544 between the two treatment groups for the differences from 
study entry to 6 months of the SUBS-SR – Last Month total and domain I, III, and VI scores, 
with α=0.05 based on a one-sided two-sample t-test (Table 3). 
To test the third hypothesis, the outcomes were analyzed by treatment and prior alcohol 
use disorder groups.  Two multiple linear regression models were developed for the third 
hypothesis.  Model 1 included the parameters treatment group and prior alcohol use disorder 
group (equation: y = β0 + βtreatment + βalcohol + ε).  Model 2 added onto Model 1 with an additional 
parameter of the interaction between treatment and prior alcohol use disorder groups (equation: y 
= β0 + βtreatment + βalcohol + βtreatment*βalcohol + ε).  As these analyses for the third hypothesis were 
exploratory, no power calculations are provided. 
SAS software, Version 9.4 14w47 for Windows was used for all statistical analyses.
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3.0  RESULTS 
Figure 1 shows the flow of participants screened, accepted into the study, and included in the 
current secondary analyses (previously described). 
3.1 AIM 1 
3.1.1 AIM 1 SAMPLE CHARACTERISTICS 
As shown in Table 4, the sample as a whole had a first manic episode onset at 22 years of age 
and was about 42 years of age at screening.  As a whole, the sample was primarily female, 
White, non-Hispanic, and never married.  The majority of participants had at least some college 
education and was either unemployed or disabled.  The HRSD-25 and YMRS scores indicate 
that the participants were not depressed or manic at study screening.  Although very few 
participants self-reported drinking a lot of alcohol in the month prior to study entry, nearly 40% 
had a prior alcohol use disorder (Table 4). 
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3.1.2 AIM 1 FINDINGS 
There were no significant changes in substance use, use of substances or drugs as self-
medication, symptoms of substance use disorder, or total substance use spectrum SUBS-SR – 
Last Month scores from study entry to 6 months among all study participants (Table 5). 
3.2 AIM 2 
3.2.1 AIM 2 CHARACTERISTICS BY TREATMENT GROUP 
There were no differences at screening between the treatment groups with respect to first manic 
episode onset age, age at study screening, gender, race, ethnicity, marital status, education, 
employment status, depression and mania levels, drank a lot of alcohol in the last month 
indicator, or prior substance use disorder rates (Table 4). 
3.2.2 AIM 2 FINDINGS 
There were no differences within either treatment group in substance use related score changes 
from study entry to 6 months, with one exception.  Within the PCMM group, there was a 
significant decrease in the use of substances or drugs as self-medication scores (domain III) 
(Table 5).  Within the IRRI group, there were no significant changes in the use of substances or 
drugs as self-medication scores (domain III) (Table 5).  When comparing results between groups, 
the change in use of substances or drugs as self-medication scores from study entry to 6 months 
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was greater in the PCMM group than the IRRI group (Table 5 footnote).  For example, Figure 2 
shows that 29% of the PCMM group improved versus 19% of the IRRI group.  There were no 
other significant differences in substance use related score changes from study entry to 6 months 
between treatment groups (Table 5). 
3.3 AIM 3 
3.3.1 AIM 3 CHARACTERISTICS BY PRIOR ALCOHOL USE DISORDER 
As shown in Table 6, the participants who had a prior alcohol use disorder were significantly less 
likely to be female and more likely to have additional prior substance use disorders than those 
with no prior alcohol use disorder.  There were no differences between the prior alcohol use 
disorder and no prior alcohol use disorder groups with respect to first manic episode onset age, 
age at study screening, race, ethnicity, marital status, education, employment status, or 
depression and mania levels (Table 6). 
In the group with no prior alcohol use disorder, as well as in the group with a prior 
alcohol use disorder, there were no differences between the treatment groups with respect to first 
manic episode onset age, age at study screening, gender, race, ethnicity, marital status, education, 
employment status, depression and mania levels, or prior substance use disorders (Table 7). 
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3.3.2 AIM 3 FINDINGS 
There were no changes in substance use related scores from study entry to 6 months within either 
of the prior alcohol use disorder groups with the exception of a decrease in self-medication 
(domain III) score changes in the prior alcohol use disorder group (Table 8).  The overall 
substance use spectrum scores decreased to a greater extent from study entry to 6 months in the 
prior alcohol use disorder group compared with the no prior alcohol use disorder group (Table 8 
footnote).  Figure 3 shows this relationship with more participants in the prior alcohol use 
disorder group improving and fewer worsening than in the no prior alcohol use disorder group.  
There were no other significant differences in substance use related score changes from study 
entry to 6 months between the prior alcohol use disorder groups (Table 8 footnote). 
There were no significant substance use related score changes from study entry to 6 
months within either of the treatment groups among those with no prior alcohol use disorder or 
those with a prior alcohol use disorder, except for a significant decrease in total spectrum scores 
in the IRRI-no prior alcohol use disorder group (Table 9). 
When factoring in treatment assignment and prior alcohol use disorder status, a multiple 
linear regression model showed that the PCMM group had significantly decreased self-
medication (domain III) change scores from study entry to 6 months compared with the IRRI 
group (Table 10).  Additionally, the prior alcohol use disorder group had significantly decreased 
self-medication (domain III) and total substance use spectrum change scores from study entry to 
6 months compared with the no prior alcohol use disorder group (Table 10).  There were no other 
significant predictors of the independent variables prior alcohol use disorder and treatment 
assignment (Model 1) (Table 10).  There were no significant interactions between treatment 
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group and prior alcohol use disorder group in Model 2, which also included the independent 
variables treatment group and prior alcohol use disorder group. 
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4.0  DISCUSSION 
The main trial from which the current analyses were conducted was a randomized, controlled 
trial comparing outcomes after IRRI treatment versus PCMM treatment.  IRRI consisted of 
psychiatric treatment, nursing management with medical monitoring, and a healthy lifestyle 
behaviors program.  PCMM consisted of psychiatric treatment and medical monitoring (less 
involved than in IRRI).  The aims of the main trial were to determine whether IRRI was superior 
to PCMM in reducing or stabilizing medical risks (such as cardiometabolic disease) and 
minimizing morbidity and mortality associated with bipolar I disorder (Frank et al., 2014).  As 
such, selected participants had remitted bipolar I disorder and a BMI of ≥ 25 kg/m2, but were 
otherwise healthy. 
The current secondary analyses of that main trial had three hypotheses.  They were that 
among overweight or obese participants with bipolar I disorder, SUBS-SR – Last Month scores 
of substance use, use of substances or drugs as self-medication, symptoms of substance use 
disorder, and total substance use spectrum would 1) decrease after undergoing 6 months of 
psychiatric treatment (IRRI or PCMM), 2) decrease more after undergoing 6 months of IRRI 
compared with PCMM, and 3) change differently among participants with a prior alcohol use 
disorder compared with participants who did not have a prior alcohol use disorder, after 
undergoing 6 months of psychiatric treatment (IRRI or PCMM), and having a prior alcohol use 
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disorder would modify the relative effect of IRRI treatment versus PCMM treatment.  These 
hypotheses were not fully supported by our findings. 
With respect to the first hypothesis, where our findings showed that there was no change 
in scores after undergoing 6 months of IRRI or PCMM treatment, the lack of hypothesis support 
could be due to combining the intervention and control groups.  If there had been an extremely 
strong difference in score changes between the treatment groups, the analysis might have shown 
significant findings.  However, as shown in Table 5, all scores remained relatively low with a 
median high of 5 points at each time point. 
The second hypothesis analyses showed similar results with the exception that, between 
treatment groups, the PCMM group had significantly decreased use of substances or drugs as 
self-medication (domain III) scores from study entry to 6 months compared with the IRRI group.  
Since the possible score for this section was 0-55 and the scores changed from 1 at study entry to 
0 at six months, this finding is not clinically meaningful.  There were no significant changes in 
the IRRI group’s outcomes.  This is not surprising since participants were chosen to be healthy 
with the exception of a high BMI.  All study participants were required to have no current 
substance use disorders, so it would not have been possible for any of their SUBS-SR – Last 
Month scores to be very high.  Since the participants started with extremely low scores (medians 
ranging 0-6, Table 5) and their scores could have been as high as 145, it was good to find that 
they did not significantly worsen with respect to any of the substance use related measures. 
This is the first analysis to show the effects of IRRI on substance use related measures.  
We speculate that PCMM participants were able to make positive changes because they were 
being treated more regularly than patients not in the study, their psychiatric medications were 
assuredly stabilized while in the study, and they were not occupied with making healthy lifestyle 
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changes (as done by IRRI participants), which may account for the significant decrease in use of 
substances or drugs as self-medication (domain III) scores seen in Table 5. 
The third hypothesis analyses added in the factor of having a prior alcohol use disorder.  
This hypothesis was developed in light of the Weiss et al. (2007) finding that participants who 
had improved substance use after an integrated group therapy were those who decreased alcohol 
use as opposed to other substances.  The findings in Table 10 indicate that having a prior alcohol 
use disorder compared with not having a prior alcohol use disorder decreased the SUBS-SR – 
Last Month outcomes of the entire sample as a whole, but did not affect participants in one 
treatment differently than the other.  This is consistent with results found in prior literature 
(Weiss et al., 2007).  We speculate that people with a prior alcohol substance use disorder may 
have been attentive to not increasing their use due to coping skills gained through programs such 
as Alcoholics Anonymous. 
The level of change seen in our results is very small and not clinically meaningful.  
Figure 4 illustrates the frequency of SUBS-SR – Last Month scores of substance use, use of 
substances or drugs as self-medication, symptoms of substance use disorder, and total substance 
use spectrum for all participants.  The statistically significant changes seen in PCMM may have 
been due to self-motivation to improve since they were not granted assignment to IRRI.  While 
the intervention did not specifically focus on substance use, the topic was included in pertinent 
sessions.  Therefore, it is possible that greater focus on substance use education may afford a 
greater result. 
Another weakness of these analyses is that selection bias may be present due to the fact 
that participants with SUBS-SR – Last Month data missing from either screening or 6 months 
were not included in the analyses.  This introduces the possibility of a type II error.  A limitation 
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of the study is that there was not much room for improvement overall because the entire sample 
was healthy aside from having remitted bipolar I disorder and being overweight or obese.  Since 
the population selected was clinically well, participants with current substance use disorders 
were naturally selected out at study screening.  It is therefore understandable that all scores upon 
study entry were on the low end of the scales (Figure 4).  The SUBS-SR – Last Month 
assessment does not collect detailed information about which substances were used or amount 
used.  The current version of the SUBS-SR – Last Month has been modified from the originally 
validated version.  Other limitations include the low power of 80% and final sample size of 87.  
These analyses were limited by the aims of the main study, which focused on reducing 
modifiable risks such as obesity, as opposed to focusing on decreasing substance use.  Although 
IRRI did not specifically focus on substance use, the topic was included in pertinent sessions. 
A strength of the study is that the research group that conducted the study is a well-
established group with 20 years of experience.  This was a new group of patients from those in 
other studies from the same research group, so there should not be any bias in the results as 
pertains to prior related research exposure.  The measures used in this study are reliable and 
valid. 
The public health relevance of this study is that decreasing substance use among patients 
with bipolar I disorder will allow for bipolar disorder symptom stabilization and, in turn, will 
decrease impacts of bipolar I disorder such as hospitalization, lost compensation, suicide, 
disability, and early mortality.  As substance use is common among this population and highly 
interfering of bipolar disorder symptom stabilization, it proves worthy of time and emphasis to 
minimize among these patients.  While psychotherapy-related treatments have been effective in 
treating comorbid bipolar and substance use disorders, we studied whether a psychotherapy-
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related treatment affected sub-threshold substance use in patients with bipolar I disorder.  If 
patients are able to manage their substance use, they will be less likely to abuse or become 
dependent on substances, and better able to manage symptoms, which will decrease their risk for 
devastating impacts. 
Future work should focus on decreasing substance use as a primary aim.  A future study 
should only analyze bipolar I disorder patients who are using substances at baseline, but who do 
not have a substance use disorder.  Patients not using substances at study entry should not be 
included in analyses. 
The current format of IRRI does not appear to have an effect on substance use spectrum 
measures after 6 months of treatment.  The level of change seen in our results is very small and, 
although statistically significant, is not clinically meaningful.  A study with greater focus on 
decreasing substance use among patients with bipolar I disorder should be developed.  The 
public health implications still remain that if patients are able to manage their substance use, they 
will be less likely to abuse or become dependent on substances, and better able to manage 
symptoms.  Hence, heavy impacts including hospitalization, lost compensation, disability, and 
suicide may be significantly decreased. 
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APPENDIX: TABLES AND FIGURES 
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Table 1. Structured modules of the Healthy Lifestyle Behaviors Program 
 
 
Component Topics addressed Therapeutic goals 
 
 
Bipolar disorder 
psychoeducation 
(3 sessions) 
 
 
 
 
 
 
Healthy 
sleep/wake and 
social rhythm 
practices 
(4 sessions) 
 
 
 
 
 
Weight loss: 
nutrition 
(4 sessions) 
 
 
 
 
 
Weight loss: 
physical activity 
(4 sessions) 
 
 
 
 
 
 
Smoking 
cessation 
(2 optional 
sessions) 
 
• Overview and rationale of the integrated risk 
reduction intervention 
• Bipolar disorder 
• Importance of a balanced lifestyle 
• Prevalence and impacts of common health 
risk behaviors in participants with bipolar 
disorder: nicotine, alcohol, and drug use 
 
 
• Sleep/wake disturbances, social rhythms, and 
mood disorders 
• Effects of nicotine, alcohol, and drugs on 
sleep and social rhythmicity 
• Eating habits and physical activity as cues to 
enhance sleep/wake and social rhythms 
• Relapse prevention for sleep/wake and social 
rhythms 
 
 
• Healthy eating habits and food choices 
• Exercise and weight loss 
• Alcohol use in weight management 
• Relapse prevention for healthy eating and 
weight loss 
 
 
 
• Education about the importance of physical 
activity and time management strategies to 
incorporate exercise in a weekly routine 
• Education about moving more and exercising 
safely 
• Identifying ways to add interest and variety 
to physical activity plan 
• How to stay motivated; relapse prevention 
 
• Interactions between nicotine and bipolar 
disorder medication 
• Stimulus control and smoking 
• Identify relationship among smoking 
behaviors, sleep and social rhythms, and 
eating habits 
• Education about symptoms of recovery from 
smoking and available resources 
 
• Increase understanding of the 
importance of balanced lifestyle 
• Identify important activities to 
enhance sleep/wake and social 
rhythms 
• Enhance adherence to self-
monitoring of sleep/wake and 
social rhythms and exercise 
 
• Continue self-monitoring of 
exercise and sleep/wake and social 
rhythms 
• Behavioral interventions to 
enhance and consolidate 
sleep/wake and social rhythm 
regularity in a gradual manner 
• Initiate self-monitoring of food 
intake 
 
• Enhance/maintain adherence to 
self- monitoring of food intake 
• Reduce calorie intake by 500 
calories per day in a progressive 
manner 
• Achieve a modest weight loss (5–
7% of initial weight) 
 
• Identify and adhere to number of 
minutes of exercise 
• Incorporate moderate-intensity 
exercise for 30 min 3–5 times per 
week in schedule 
 
 
 
 
• Self-monitor smoking behaviors 
and triggers 
• Identify benefits of and coping 
skills to quit smoking 
• Plan smoking cessation 
 
 
Adapted from Frank, E., Wallace, M. L., Hall, M., Hasler, B., Levenson, J. C., Janney, C. A., . . . Kupfer, D. J. (2014). An 
Integrated Risk Reduction Intervention can reduce body mass index in individuals being treated for bipolar I 
disorder: results from a randomized trial. Bipolar Disord. doi: 10.1111/bdi.12283 
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Table 2. Effect sizes at various levels of power for analysis of study hypothesis 1 Self-Report Last Month 
Substance Use Spectrum assessment (SUBS-SR – Last Month) completed at study entry and 6 months, based 
on a one-sided paired t-test 
 
N Power Alpha Mean of paired 
differences 
Standard 
deviation 
Effect size 
85 80% 0.05 0.272 1 0.272 
85 90% 0.05 0.320 1 0.320 
85 95% 0.05 0.360 1 0.360 
85 99% 0.05 0.434 1 0.434 
Note: The boxed figures are those which will be analyzed for study hypothesis 1. 
 
 
Table 3. Effect sizes at various levels of power for analysis of study hypothesis 2 Self-Report Last Month 
Substance Use Spectrum assessment (SUBS-SR – Last Month) completed at study entry and 6 months, based 
on a one-sided two-sample t-test 
 
IRRI (N) PCMM 
(N) 
Power 
(1-β) 
α IRRI μ PCMM μ IRRI σ PCMM σ Effect 
size 
41 44 80% 0.05 0.544 0 1 1 0.544 
41 44 90% 0.05 0.640 0 1 1 0.640 
41 44 95% 0.05 0.720 0 1 1 0.720 
41 44 99% 0.05 0.869 0 1 1 0.869 
Note: The boxed figures are those which will be analyzed for study hypothesis 2.  Abbreviations: IRRI=integrated 
risk reduction intervention, PCMM=psychiatric care with medical monitoring 
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Table 4. Sample characteristics for all participants and by treatment group at study screen 
 
  
All Participants IRRI PCMM
(N=114) (n=58) (n=56)
Treatment Assignment (% IRRI (n)) 50.88 (58)
Age at Onset of First Mania Episode (median (25%, 75%)) 22.0 (17.0, 29.0) 21.0 (16.5, 28.5) 22.0 (18.0, 29.0) 0.40b
Age at Study Screening (median (25%, 75%)) 42.2 (34.0, 49.0) 42.7 (34.8, 49.0) 41.8 (33.6, 49.6) 0.90b
Gender (% female (n)) 58.77 (67) 60.34 (35) 57.14 (32) 0.73c
Race (% White (n)) 85.84 (97) 85.96 (49) 85.71 (48) 0.97c
Ethnicity (% non-Hispanic (n)) 100.00 (114) 100.00 (58) 100.00 (56)
Marital Status: Never Married (Never Lived as Married) (% (n)) 42.98 (49) 41.38 (24) 44.64 (25)
Married or Living as Married (% (n)) 35.96 (41) 34.48 (20) 37.50 (21)
Divorced, Widowed, or Separated/No Longer Living as Married
(% (n))
21.05 (24) 24.14 (14) 17.86 (10)
Education: High School or Less (% (n)) 11.40 (13) 12.07 (7) 10.71 (6)
Some College (% (n)) 41.23 (47) 36.21 (21) 46.43 (26)
College Diploma (Bachelor's Degree) (% (n)) 28.95 (33) 31.03 (18) 26.79 (15)
Graduate or Professional Degree (% (n)) 18.42 (21) 20.69 (12) 16.07 (9)
Employment Status: Full-time (35 or More Hours Per Week) for Pay
         (% (n))
22.81 (26) 24.14 (14) 21.43 (12)
Part-time for Pay (% (n)) 19.30 (22) 15.52 (9) 23.21 (13)
Homemaker or Unemployed (% (n)) 30.70 (35) 29.31 (17) 32.14 (18)
Disabled or Leave of Absence (% (n)) 27.19 (31) 31.03 (18) 23.21 (13)
Hamilton Rating Scale for Depression (25) Score (median (25%, 75%)) 6.0 (4.0, 9.0) 6.0 (3.0, 9.0) 6.0 (4.0, 9.0) 0.93b
Young Mania Rating Scale Score (median (25%, 75%)) 0.0 (0.0, 2.0) 1.0 (0.0, 3.0) 0.0 (0.0, 2.0) 0.08b
Drank a lot of alcohol in the last month at study entrya (% yes (n)) 7.14 (8) 7.02 (4) 7.27 (4) 1.00d
LIFETIME SUBSTANCE USE DISORDERS
Alcohol (% lifetime threshold (n)) 37.72 (43) 41.38 (24) 33.93 (19) 0.41c
Cannabis (% lifetime threshold (n)) 16.67 (19) 18.97 (11) 14.29 (8) 0.50c
Cocaine (% lifetime threshold (n)) 10.53 (12) 12.07 (7) 8.93 (5) 0.58c
Other or Poly Substance (% lifetime threshold (n)) 14.91 (17) 17.24 (10) 12.50 (7) 0.48c
IRRI=integrated risk reduction intervention; PCMM=psychiatric care with medical monitoring; aSUBS-SR – Last Month question 3 “In the past 
month, have you had periods in which you drank a lot of alcohol?”; bWilcoxon Rank Sums, cChi-Square, dFisher's Exact Test.  All p-values are two-
sided.
0.74d
 0.74d
0.64d
Between 
Treatment 
Groups p-value
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Table 5. Outcome measures for all participants and by treatment group at study entry, month 6, and change from study entry to month 6 
 
  
Study Entry Month 6
Change from Study 
Entry to Month 6
All Participants N median (25%, 75%) median (25%, 75%) median (25%, 75%)
Domain I: Substance Use Score 85 1.0 (0.0, 2.0) 1.0 (0.0, 3.0) 0.0 (-1.0, 1.0) 0.08
Domain III: Self-Medication Score 79 1.0 (0.0, 3.0) 0.0 (0.0, 2.0) 0.0 (0.0, 1.0) 0.18
Domain VI: Substance Use Disorder Symptoms Score 84 0.0 (0.0, 1.0) 0.0 (0.0, 1.0) 0.0 (0.0, 0.0) 0.39
Substance Use Spectrum Total Score 74 5.0 (3.0, 9.0) 5.0 (2.0, 9.0) 0.0 (-2.0, 3.0) 0.43
IRRI n
Domain I: Substance Use Score 42 1.0 (0.0, 2.0) 1.0 (0.0, 3.0) 0.0 (-1.0, 1.0) 0.10
Domain III: Self-Medication Score 39 1.0 (0.0, 3.0) 1.0 (0.0, 4.0) 0.0 (-1.0, 1.0) 0.25
Domain VI: Substance Use Disorder Symptoms Score 40 0.0 (0.0, 2.0) 0.0 (0.0, 2.0) 0.0 (-0.5, 1.0) 0.35
Substance Use Spectrum Total Score 37 4.0 (3.0, 9.0) 4.0 (2.0, 10.0) 0.0 (-4.0, 2.0) 0.28
PCMM n
Domain I: Substance Use Score 43 1.0 (0.0, 2.0) 1.0 (0.0, 3.0) 0.0 (-1.0, 1.0) 0.27
Domain III: Self-Medication Score 40 1.0 (0.0, 3.0) 0.0 (0.0, 2.0) 0.0 (0.0, 1.5) 0.02*
Domain VI: Substance Use Disorder Symptoms Score 44 0.0 (0.0, 1.0) 0.0 (0.0, 1.0) 0.0 (0.0, 0.0) 0.47
Substance Use Spectrum Total Score 37 6.0 (3.0, 9.0) 5.0 (2.0, 8.0) 0.0 (-1.0, 3.0) 0.19
IRRI=integrated risk reduction intervention; PCMM=psychiatric care with medical monitoring; All p-values in the table are from one-sided Wilcoxon 
Signed Rank tests.  Results described below are from Wilcoxon Rank Sum tests.
*Based on a one-sided test, the change in the use of substances or drugs as self-medication scores (domain III) from study entry to 6 months was 
significantly higher in the PCMM group than the IRRI group (p-value<0.05).  No other substance use related score changes from study entry to 6 months 
were different (based on one-sided tests) between the treatment groups.
Change from 
Study Entry to 
Month 6 p-value
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Table 6. Sample characteristics by prior alcohol use disorder group at study screen 
 
No Prior Alcohol 
Use Disorder
Prior Alcohol Use 
Disorder
(n=71) (n=43)
Treatment Assignment (% IRRI (n)) 47.89 (34) 55.81 (24) 0.41b
Age at Onset of First Mania Episode (median (25%, 75%)) 21.0 (17.0, 26.0) 22.5 (17.0, 31.0) 0.80a
Age at Study Screening (median (25%, 75%)) 40.6 (33.9, 48.7) 44.5 (34.0, 51.1) 0.40a
Gender (% female (n)) 69.01 (49) 41.86 (18) <0.01b
Race (% White (n)) 83.10 (59) 90.48 (38) 0.28b
Ethnicity (% non-Hispanic (n)) 100.00 (71) 100.00 (43)
Marital Status: Never Married (Never Lived as Married) (% (n)) 40.85 (29) 46.51 (20)
Married or Living as Married (% (n)) 38.03 (27) 32.56 (14)
Divorced, Widowed, or Separated/No Longer Living as Married (% (n)) 21.13 (15) 20.93 (9)
Education: High School or Less (% (n)) 11.27 (8) 11.63 (5)
Some College (% (n)) 42.25 (30) 39.53 (17)
College Diploma (Bachelor's Degree) (% (n)) 29.58 (21) 27.91 (12)
Graduate or Professional Degree (% (n)) 16.90 (12) 20.93 (9)
Employment Status: Full-time (35 or More Hours Per Week) for Pay (% (n)) 22.54 (16) 23.26 (10)
Part-time for Pay (% (n)) 21.13 (15) 16.28 (7)
Homemaker or Unemployed (% (n)) 32.39 (23) 27.91 (12)
Disabled or Leave of Absence (% (n)) 23.94 (17) 32.56 (14)
Hamilton Rating Scale for Depression (25) Score (median (25%, 75%)) 6.0 (4.0, 9.0) 6.0 (4.0, 9.0) 0.79a
Young Mania Rating Scale Score (median (25%, 75%)) 1.0 (0.0, 3.0) 0.0 (0.0, 2.0) 0.14a
LIFETIME SUBSTANCE USE DISORDERS
Cannabis (% lifetime threshold (n)) 9.86 (7) 27.91 (12) 0.01b
Cocaine (% lifetime threshold (n)) 7.04 (5) 16.28 (7) 0.21c
Other or Poly Substance (% lifetime threshold (n)) 5.63 (4) 30.23 (13) <0.01b
aWilcoxon Rank Sums, bChi-Square, cFisher's Exact Test.  All p-values are two-sided.
0.83c
0.96c
0.76c
Between Prior 
Alcohol Use 
Disorder Groups 
p-value
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Table 7. Sample characteristics by prior alcohol use disorder group and treatment group at study screen 
 
  
IRRI PCMM IRRI PCMM
(N=34) (N=37) (N=24) (N=19)
Age at Onset of First Mania Episode
         (median (25%, 75%))
22.0
(17.0, 28.0)
21.0
(18.0, 25.0) 0.90
a 20.0
(16.0, 30.0)
24.0
(18.0, 31.0) 0.22
a
Age at Study Screening (median (25%, 75%)) 41.2
(36.0, 48.7)
40.6
(33.2, 48.7) 0.73
a 44.5
(33.7, 49.9)
42.1
(37.7, 52.5) 0.73
a
Gender (% female (n)) 70.59 (24) 67.57 (25) 0.78b 45.83 (11) 36.84 (7) 0.55b
Race (% White (n)) 82.35 (28) 83.78 (31) 0.87b 91.30 (21) 89.47 (17) 1.00c
Ethnicity (% non-Hispanic (n)) 100.00 (34) 100.00 (37) 100.00 (24) 100.00 (19)
Marital Status: Never Married (Never Lived as
          Married) (% (n))
32.35 (11) 48.65 (18) 54.17 (13) 36.84 (7)
Married or Living as Married (% (n)) 44.12 (15) 32.43 (12) 20.83 (5) 47.37 (9)
Divorced, Widowed, or Separated/No Longer Living as 
Married (% (n))
23.53 (8) 18.92 (7) 25.00 (6) 15.79 (3)
Education: High School or Less (% (n)) 11.76 (4) 10.81 (4) 12.50 (3) 10.53 (2)
Some College (% (n)) 41.18 (14) 43.24 (16) 29.17 (7) 52.63 (10)
College Diploma (Bachelor's Degree) (% (n)) 29.41 (10) 29.73 (11) 33.33 (8) 21.05 (4)
Graduate or Professional Degree (% (n)) 17.65 (6) 16.22 (6) 25.00 (6) 15.79 (3)
Employment Status: Full-time (35 or More Hours Per
         Week) for Pay (% (n))
26.47 (9) 18.92 (7) 20.83 (5) 26.32 (5)
Part-time for Pay (% (n)) 14.71 (5) 27.03 (10) 16.67 (4) 15.79 (3)
Homemaker or Unemployed (% (n)) 35.29 (12) 29.73 (11) 20.83 (5) 36.84 (7)
Disabled or Leave of Absence (% (n)) 23.53 (8) 24.32 (9) 41.67 (10) 21.05 (4)
Hamilton Rating Scale for Depression (25) Score
         (median (25%, 75%))
6.0
(3.0, 9.0)
6.0
(4.0, 9.0) 0.88
a 6.0
(3.5, 8.5)
6.0
(4.0, 9.0) 0.79
a
Young Mania Rating Scale Score (median (25%, 75%)) 1.5
(0.0, 3.0)
0.0
(0.0, 2.0) 0.23
a 1.0
(0.0, 2.0)
0.0
(0.0, 1.0) 0.09
a
LIFETIME SUBSTANCE USE DISORDERS
Cannabis (% lifetime threshold (n)) 5.88 (2) 13.51 (5) 0.43c 37.50 (9) 15.79 (3) 0.12b
Cocaine (% lifetime threshold (n)) 5.88 (2) 8.11 (3) 1.00c 20.83 (5) 10.53 (2) 0.44c
Other or Poly Substance (% lifetime threshold (n)) 2.94 (1) 8.11 (3) 0.62c 37.50 (9) 21.05 (4) 0.24b
Between 
Treatment 
Groups p-value
Between 
Treatment 
Groups p-value
No Prior Alcohol Use Disorder Prior Alcohol Use Disorder
IRRI=integrated risk reduction intervention; PCMM=psychiatric care with medical monitoring; aWilcoxon Rank Sums, bChi-Square, cFisher's Exact Test.  All p-
values are two-sided.
0.40c 0.19c
1.00c 0.54c
0.61c 0.52c
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Table 8. Outcome measures by prior alcohol use disorder group at study entry, month 6, and change from study entry to month 6 
 
 
  
No Prior Alcohol Use Disorder n
Study Entry
median (25%, 75%)
Month 6
median (25%, 75%)
Change from Study 
Entry to Month 6
median (25%, 75%)
Change from 
Study Entry to 
Month 6 p-value
Domain I: Substance Use Score 53 1.0 (0.0, 2.0) 1.0 (0.0, 3.0) 0.0 (-1.0, 1.0) 0.17
Domain III: Self-Medication Score 47 1.0 (0.0, 3.0) 0.0 (0.0, 2.0) 0.0 (-1.0, 1.0) 0.41
Domain VI: Substance Use Disorder Symptoms Score 50 0.0 (0.0, 1.0) 0.0 (0.0, 1.0) 0.0 (0.0, 0.0) 0.26
Substance Use Spectrum Total Score 46 5.0 (2.0, 9.0) 5.0 (2.0, 10.0) 0.0 (-3.0, 2.0) 0.18
Prior Alcohol Use Disorder
Domain I: Substance Use Score 32 1.0 (0.0, 2.0) 2.0 (0.5, 2.5) 0.0 (-1.0, 0.0) 0.15
Domain III: Self-Medication Score 32 1.0 (0.0, 3.0) 0.0 (0.0, 1.5) 0.0 (0.0, 2.0) 0.04
Domain VI: Substance Use Disorder Symptoms Score 34 0.0 (0.0, 2.0) 0.0 (0.0, 1.0) 0.0 (0.0, 0.0) 0.35
Substance Use Spectrum Total Score 28 5.5 (4.0, 10.0) 5.0 (3.0, 8.5) 1.0 (-1.0, 5.5) 0.08*
Notes: All p-values in the table are from one-sided Wilcoxon Signed Rank tests.  Results described below are all based on Wilcoxon Rank Sum tests.
*Based on a one-sided test, the change in total substance use spectrum score from study entry to 6 months was significantly higher in the 
lifetime alcohol use disorder group compared with the no lifetime alcohol use disorder group (p-value=0.02).  There were no other significant 
differences in substance use related score changes from study entry to 6 months (based on one-sided tests) between the lifetime alcohol use disorder 
groups.
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Table 9. Outcome measures by prior alcohol use disorder group and treatment group at study entry, month 6, and change from study entry to month 6 
 
 
  
No Prior Alcohol Use Disorder
IRRI n
Study Entry
median (25%, 75%)
Month 6
median (25%, 75%)
Change from Study 
Entry to Month 6
median (25%, 75%)
Change from 
Study Entry to 
Month 6 p-value
Domain I: Substance Use Score 24 1.0 (0.0, 2.0) 1.0 (0.0, 3.0) 0.0 (-1.0, 0.5) 0.14
Domain III: Self Medication Score 22 1.0 (0.0, 2.0) 1.0 (0.0, 8.0) 0.0 (-2.0, 0.0) 0.07
Domain VI: Substance Use Disorder Symptoms Score 22 0.0 (0.0, 1.0) 0.0 (0.0, 3.0) 0.0 (-1.0, 1.0) 0.25
Substance Use Spectrum Total Score 21 3.0 (2.0, 9.0) 5.0 (1.0, 15.0) -1.0 (-6.0, 2.0) 0.04
PCMM
Domain I: Substance Use Score 29 1.0 (1.0, 2.0) 1.0 (0.0, 2.0) 0.0 (-1.0, 1.0) 0.43
Domain III: Self Medication Score 25 1.0 (0.0, 3.0) 0.0 (0.0, 2.0) 0.0 (0.0, 1.0) 0.09
Domain VI: Substance Use Disorder Symptoms Score 28 0.0 (0.0, 1.0) 0.0 (0.0, 1.0) 0.0 (0.0, 0.0) 0.47
Substance Use Spectrum Total Score 25 6.0 (2.0, 8.0) 5.0 (2.0, 8.0) 0.0 (-1.0, 2.0) 0.30
Prior Alcohol Use Disorder
IRRI
Domain I: Substance Use Score 18 1.0 (1.0, 2.0) 1.0 (1.0, 2.0) 0.0 (-1.0, 1.0) 0.34
Domain III: Self Medication Score 17 1.0 (0.0, 3.0) 0.0 (0.0, 1.0) 0.0 (0.0, 1.0) 0.19
Domain VI: Substance Use Disorder Symptoms Score 18 1.0 (0.0, 3.0) 0.0 (0.0, 1.0) 0.0 (0.0, 1.0) 0.42
Substance Use Spectrum Total Score 16 5.5 (4.0, 10.0) 4.0 (3.0, 8.0) 1.0 (0.0, 5.0) 0.10
PCMM
Domain I: Substance Use Score 14 1.5 (0.0, 2.0) 2.0 (0.0, 3.0) 0.0 (-1.0, 0.0) 0.22
Domain III: Self Medication Score 15 0.0 (0.0, 3.0) 0.0 (0.0, 2.0) 0.0 (0.0, 2.0) 0.08
Domain VI: Substance Use Disorder Symptoms Score 16 0.0 (0.0, 0.5) 0.0 (0.0, 0.5) 0.0 (0.0, 0.0) 0.42
Substance Use Spectrum Total Score 12 5.5 (3.5, 10.0) 6.0 (3.0, 11.0) 1.5 (-1.5, 5.5) 0.26
IRRI=integrated risk reduction intervention; PCMM=psychiatric care with medical monitoring; All p-values in the table are from one-sided Wilcoxon Signed Rank tests.
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Table 10. Multiple linear regression Model 1 (predictors=treatment and prior alcohol use disorder) for each substance use related score change 
outcome 
 
 
 
Change in Domain I: Substance Use Score
(n=85, R2<0.01) Estimated Beta
Standard Error 
of Beta p-value
Intercept -0.14 0.23 0.54
IRRI (vs. PCMM) -0.19 0.29 0.51
Prior Alcohol Use Disorder (vs. No Prior Alcohol Use Disorder) < 0.00 0.30 0.99
Change in Domain III: Use of Substances or Drugs as Self-
Medication Score (n=79, R2=0.10)
Intercept 0.28 0.47 0.56
IRRI (vs. PCMM) -1.36 0.59 0.02
Prior Alcohol Use Disorder (vs. No Prior Alcohol Use Disorder) 1.20 0.60 0.05
Change in Domain VI: Symptoms of Substance Use Disorder 
Score (n=84, R2=0.02)
Intercept -0.46 0.47 0.33
IRRI (vs. PCMM) -0.28 0.60 0.64
Prior Alcohol Use Disorder (vs. No Prior Alcohol Use Disorder) 0.75 0.61 0.22
Change in Total Substance Use Spectrum Score
(n=74, R2=0.08)
Intercept -0.98 1.24 0.43
IRRI (vs. PCMM) -2.15 1.59 0.18
Prior Alcohol Use Disorder (vs. No Prior Alcohol Use Disorder) 3.60 1.64 0.03
IRRI=integrated risk reduction intervention; PCMM=psychiatric care with medical monitoring
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Figure 1. Flow chart of participants in substance use spectrum analyses 
*Section: Domain I (substance use, questions 1-22), domain III (self-medication, questions 42-96), domain VI 
(substance use disorder symptoms, questions 109-131), or total substance use spectrum (all questions: 1-131) 
from the Self-Report Last Month Substance Use Spectrum assessment (SUBS-SR – Last Month). 
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Figure 2. Comparison between treatment groups of change in past month self-medication (domain III) Self-Report Last Month Substance Use 
Spectrum assessment (SUBS-SR – Last Month) scores from study entry to six months 
IRRI=integrated risk reduction intervention; PCMM=psychiatric care with medical monitoring 
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Figure 3. Comparison between prior alcohol use disorder groups of change in past month total Self-Report Last Month Substance Use Spectrum 
assessment (SUBS-SR – Last Month) scores from study entry to six months 
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A.          B. 
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C.          D. 
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Figure 4. Comparison of past month total Self-Report Last Month Substance Use Spectrum assessment (SUBS-SR – Last Month) scores from study 
entry and six months 
A. Domain I of the SUBS-SR – Last Month – Substance use 
B. Domain III of the SUBS-SR – Last Month - Use of substances or drugs as self-medication 
C. Domain VI of the SUBS-SR – Last Month – Symptoms of substance use disorder 
D. Total score of the SUBS-SR – Last Month 
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